Health Trials

Precision Medicine for Every Child With Cancer

ConditionsChildhood CancerChildhood Solid TumorChildhood Brain TumorChildhood LeukemiaRefractory CancerRelapsed Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age0-25
SponsorAustralian & New Zealand Children's Haematology/Oncology Group

About this trial

To improve outcomes for childhood cancer patients through the implementation of precision medicine.

Eligibility criteria

Qualifiers

Age < 18 years Note: Individual patients aged 19 - 25 years old with a pediatric cancer, e.g., neuroblastoma, may be enrolled after discussion with, and at the discretion of, the Study Chair or their delegate.

Life expectancy >6 weeks at time of enrolment

Consent i. Signed and dated informed consent for study enrolment from participant aged ≥ 18 years or from parent/guardian of participant aged <18 years. ii. Separate signed and dated informed consent for understanding the role of germline testing and choice for the return of germline results.

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Whole Genome Sequencing
  • RNA seq
  • DNA Methylation
  • Targeted Panel Sequencing
  • High Throughput Sequencing (in vitro)
  • Patient Derived Xenograft (PDX)(in vivo)
  • Liquid Biopsy

Treatment groups

3,500 Participants
are divided into 13 treatment groups

13

Treatment groups

See each treatment group below.

Sponsors and collaborators

Australian & New Zealand Children's Haematology/Oncology Group

Lead sponsor

Children's Cancer Institute (CCI)

Collaborator

Minderoo Foundation

Collaborator

Medical Research Future Fund

Collaborator

Source ClinicalTrials.gov